Shares of Keryx (NASDAQ:KERX) got a boost on Thursday thanks to the decision-makers in the halls of Congress. The "Doc Fix" Medicare legislation, which just passed the House of Representatives, included language that exempts end-stage renal disease drugs from the reduced payment bundle until 2024, instead of 2016. This directly affects Keryx's lead drug candidate Zerenex, which removes extra phosphorous from patients on dialysis.

In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass dig into what the legislation means for the company, what the potential is for Zerenex, and what to watch for on June 7, when the FDA makes its approval decision.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.